Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,689.67 +2,018.31 (+3.27%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Roche Holding AG (RHO6.BE)
| Previous close | 27.40 |
| Open | 27.40 |
| Bid | 27.40 x 0 |
| Ask | 28.10 x 0 |
| Day's range | 27.40 - 27.70 |
| 52-week range | 27.30 - 37.80 |
| Volume | |
| Avg. volume | 4 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- MediaOutReach
Advancing Healthcare Access: ScreenHer initiative in Pakistan close to reaching milestone of 20,000 diabetes screenings in 70 clinics
A collaboration between Roche Diabetes Care and social enterprise Greenstar Social Marketing, ScreenHer seeks to improve women’s access to diabetes care KARACHI, PAKISTAN - Media Outreach Newswire - 26 February 2024 - Roche Diabetes Care Pakistan (Roche) and social enterprise Greenstar Social Marketing (Guarantee) Limited (Greenstar) are pleased to announce a significant milestone for the ScreenHer initiative, which enables women in the rural and peri-urban areas to access diabetes risk assessme
- Yahoo Finance Video
What To Watch: Novo Nordisk
Novo Nordisk (NVO), the Danish drugmaker behind Ozempic & Wegovy has become a household name and one of Europe's most valuable companies. What To Watch focuses in on three key issues as Novo Nordisk reports 4th quarter earnings on January 25th: 1. Expansion: 3rd quarter results were music to investors ears with a 29% jump in sales to 8.4 billion dollars. The unprecedented off label sales of its diabetes drug Ozempic started a stampeded to keep up with demand & a global surge in counterfeits. Novo’s deal is worth up to 1 billion dollars with U.S. biotech startups and plans for expanding capacity will be watched with interest. 2. Competitors: Eli Lilly (LLY) is in hot pursuit though diabetes drug Mounjaro and with obesity drug Zepbound after FDA approval in November. Lilly also started a new website to connect patients seeking treatment with Telehealth providers. Then there is Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), & Astra Zeneca (AZN) all fighting for a piece of the pie. The battle is on for a share of the market that could be worth 100 billion dollars by the end of the decade. 3. Barriers: There are many hurdles for Novo Nordisk. For one, Medicare does not cover weight loss drugs & Novo has been lobbying Congress to release these restrictions. Some insurers are hesitant to cover or have strict prior authorization rules in place. Can Novo keep as much supply as Eli Lilly ramps up their production capacity? Lots to digest as we wait to see how one of the biggest stories in business news develops.
- Yahoo Finance
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.
